Kindred Biosciences, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kindred Biosciences, Inc. (KIN) develops and commercializes innovative biologics and therapeutics for pets, focusing on dogs, cats and horses; core products include Mirataz (mirtazapine transdermal ointment) for weight loss management in cats, Zimeta (dipyrone injection) for fever control in horses, and a pipeline of monoclonal antibodies such as KIND-016, KIND-032 and KIND-025 targeting interleukin-31, interleukin-4 receptor and IL-4/IL-13 for canine atopic dermatitis; KIND-030 for canine parvovirus prophylaxis; KIND-509 for canine inflammatory bowel disease; KIND-510a for non-regenerative anemia in cats; and KIND-511 for anti-tumor necrosis factor treatment in foals. The company operates in the veterinary biopharmaceutical sector, translating validated human targets into pet medicines across dermatology, infectious diseases, gastroenterology and hematology; it targets veterinarians and pet owners primarily in the United States with manufacturing facilities including sites in Burlingame, California, and Elwood, Kansas. Founded in 2012 and headquartered in Burlingame, California, Kindred Biosciences entered into a definitive agreement in June 2021 for acquisition by Elanco Animal Health for $440 million at $9.25 per share, which closed in August 2021, integrating its pipeline into Elanco's pet health portfolio and adding nearly $100 million to innovation revenue projections by 2025.
SHAREHOLDER ALERT: WeissLaw LLP Reminds CVA, SWN, RIVE, and KIN Shareholders About Its Ongoing Investigations
Moore Kuehn Encourages KIN, SVOK, ROCR, and DCRC Investors to Contact Law Firm
KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kindred Biosciences, Inc. - KIN
Why Kindred Biosciences Stock Skyrocketed Today
Kindred Biosciences to merge with Elanco Animal Health
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kindred Biosciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KIN
KIN Stock Price Increases Over 45% Pre-Market: Why It Happened
Elanco Animal Health to acquire Kindred Biosciences for about $440 million; Kindred shares soar 45% premarket
Elanco Announces Agreement to Acquire Kindred Biosciences
Kindred Bio (KIN) Soars 16%: Is Further Upside Left in the Stock?
Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI
Kindred Biosciences, Inc. (KIN) CEO Dr. Richard Chin on Q1 2021 Results - Earnings Call Transcript
Kindred Biosciences Announces First Quarter 2021 Financial Results
Kindred Biosciences to Announce First Quarter 2021 Financial Results
Week 18 MDA Breakout Stocks - May 2021: Short-Term Picks To Give You An Edge
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Steven Cohen Adopts Stake in Kindred Biosciences
Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2020 Results - Earnings Call Transcript